Patents by Inventor Thierry Guyon

Thierry Guyon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Publication number: 20130243855
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Application
    Filed: November 14, 2012
    Publication date: September 19, 2013
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • Modified coagulation factor IX polypeptides and use thereof for treatment
    Patent number: 8383388
    Abstract: Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: February 26, 2013
    Assignee: Catalyst Biosciences, Inc.
    Inventors: Jorge Oyhenart, Xavier Gallet, Gilles Borrelly, Thierry Guyon, Manuel Vega, Lila Drittanti
  • MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120264686
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: October 18, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified erythropoietin polypeptides and uses thereof for treatment
    Patent number: 8252743
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: August 28, 2012
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Modified growth hormones that exhibit increased protease resistance and pharmaceutical compositions thereof
    Patent number: 8222209
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Grant
    Filed: January 25, 2011
    Date of Patent: July 17, 2012
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES THAT EXHIBIT INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
    Publication number: 20120094906
    Abstract: Modified erythropoietin (EPO) polypeptides and other modified therapeutic polypeptides are provided. The EPO polypeptides and other therapeutic polypeptides are modified to exhibit physical properties and activities that differ from the unmodified EPO polypeptides and other unmodified therapeutic polypeptides, respectively. Nucleic acid molecules encoding these polypeptides also are provided. Also provided are methods of treatment and diagnosis using the polypeptides.
    Type: Application
    Filed: May 29, 2009
    Publication date: April 19, 2012
    Inventors: Thierry Guyon, Gilles Borrelly, Xavier Gallet, Lila Drittanti, Manuel Vega
  • Protease resistant modified erythropoietin polypeptides
    Patent number: 8114839
    Abstract: Modified erythropoietin polypeptides that include the mutation R131Q, and uses thereof are provided. Also provided are pharmaceutical compositions, including compositions formulated for oral administration, that contain the modified erythropoietin polypeptides and uses of the compositions to treat diseases and conditions treated by erythropoietin.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 14, 2012
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • Protease resistant modified IFN beta polypeptides and their use in treating diseases
    Patent number: 8105573
    Abstract: Protease resistant modified interferon-beta polypeptides, and pharmaceutical compositions containing such modified interferon-beta polypeptides are provided. The modified interferon-beta polypeptides contain amino acid substitutions that confer increased resistance to proteolysis over unmodified IFN beta cytokine molecules. The present invention provides for pharmaceutical formulations suitable for oral, nasal and pulmonary administration, and the use of such formulations in the treatment of disease.
    Type: Grant
    Filed: January 26, 2011
    Date of Patent: January 31, 2012
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • HMGB1 high affinity binding domain Box-A mutants
    Patent number: 8058232
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: November 15, 2011
    Assignee: Creabilis Therapeutics S.p.A.
    Inventors: Silvano Fumero, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Protease resistant modified interferon-beta polypeptides
    Patent number: 8057787
    Abstract: Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: November 15, 2011
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • Interferon-? mutants with increased anti-proliferative activity
    Patent number: 8052964
    Abstract: Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment by administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: November 8, 2011
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • Protease resistant interferon beta mutants
    Patent number: 7998469
    Abstract: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.
    Type: Grant
    Filed: February 13, 2007
    Date of Patent: August 16, 2011
    Assignee: Hanall Biopharma Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • Modified growth hormones
    Patent number: 7998930
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 16, 2011
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • PROTEASE RESISTANT MODIFIED INTERFERON-BETA POLYPEPTIDES AND THEIR USE IN TREATING DISEASES
    Publication number: 20110142801
    Abstract: Protease resistant modified interferon-beta polypeptides, pharmaceutical compositions and methods of treatment by administering the compositions are provided. The modified interferon-beta polypeptides are orally available; hence pharmaceutical compositions formulated for oral administration also are provided.
    Type: Application
    Filed: January 26, 2011
    Publication date: June 16, 2011
    Applicant: HANALL BIOPHARMA CO., LTD.
    Inventors: Rene GANTIER, Manuel VEGA, Lila DRITTANTI, Thierry GUYON
  • Modified growth hormones
    Publication number: 20110130331
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Application
    Filed: January 25, 2011
    Publication date: June 2, 2011
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • USE OF POLYPEPTIDES OBTAINED THROUGH SYSTEMATIC MUTATIONS OF SINGLE AMINO ACIDS OF HUMAN AND NON-HUMAN BOX-A OF HMGB1 TO PREVENT AND/OR ANTAGONIZE PATHOLOGIES INDUCED BY HMGB1
    Publication number: 20110052493
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favourable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Application
    Filed: November 9, 2009
    Publication date: March 3, 2011
    Applicant: CREABILIS THERAPEUTICS S.P.A.
    Inventors: Silvano FUMERO, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Modified growth hormone
    Patent number: 7884073
    Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.
    Type: Grant
    Filed: June 26, 2006
    Date of Patent: February 8, 2011
    Assignee: HanAll BioPharma Co., Ltd.
    Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
  • Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
    Patent number: 7650243
    Abstract: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated by cytokines.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: January 19, 2010
    Assignee: Hanall Pharmaceutical Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon
  • Protease resistant mutant of human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A)
    Patent number: 7635679
    Abstract: The present invention relates to polypeptide variants of the HMGB-1 high affinity binding domain Box-A (HMGB1 Box-A) or to a biologically active fragment of HMGB1 Box-A, which are obtained through systematic mutations of single amino acids of the wild-type HMGB1 Box-A protein and which show an increased resistance to proteases and which are therefore characterized by more favorable pharmacokinetic and pharmacodynamic profiles. Moreover, the present invention concerns the use of said polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and associated with RAGE.
    Type: Grant
    Filed: March 5, 2007
    Date of Patent: December 22, 2009
    Assignee: Creabilis Therapeutics S.p.A.
    Inventors: Silvano Fumero, Luisa Bertarione Rava Rossa, Domenico G. Barone, Lila Drittanti, Thierry Guyon, Gilles Borrelly, Barbara Canepa, Chiara Lorenzetto
  • Protease resistant modified interferon alpha polypeptides
    Patent number: 7611700
    Abstract: Processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided is a rational method for generating protein variants and the resulting variants.
    Type: Grant
    Filed: September 8, 2003
    Date of Patent: November 3, 2009
    Assignee: Hanall Pharmaceuticals, Co., Ltd.
    Inventors: Rene Gantier, Manuel Vega, Lila Drittanti, Thierry Guyon